Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 6, 2021; 9(22): 6478-6484
Published online Aug 6, 2021. doi: 10.12998/wjcc.v9.i22.6478
Published online Aug 6, 2021. doi: 10.12998/wjcc.v9.i22.6478
Primary small cell esophageal carcinoma, chemotherapy sequential immunotherapy: A case report
Yong-Hui Wu, Kai Zhang, Wei-Bin Wu, Xiao-Jun Li, Jian Zhang, Department of Cardiothoracic Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, Guangdong Province, China
Hui-Guo Chen, Department of Thoracic Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, Guangdong Province, China
Author contributions: Wu YH designed the report and wrote the paper; Zhang K, Chen HG and Wu WB collected the patient’s medical imaging materials; Li XJ and Zhang J participated in the revision of this article.
Informed consent statement: Consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian Zhang, PhD, Assistant Professor, Department of Cardiothoracic Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, No. 600 Tianhe Road, Guangzhou 510630, Guangdong Province, China. sumszhangjian@163.com
Received: April 2, 2021
Peer-review started: April 2, 2021
First decision: April 28, 2021
Revised: May 16, 2021
Accepted: June 1, 2021
Article in press: June 1, 2021
Published online: August 6, 2021
Processing time: 116 Days and 14.9 Hours
Peer-review started: April 2, 2021
First decision: April 28, 2021
Revised: May 16, 2021
Accepted: June 1, 2021
Article in press: June 1, 2021
Published online: August 6, 2021
Processing time: 116 Days and 14.9 Hours
Core Tip
Core Tip: A 79-year-old male was diagnosed primary small cell esophageal carcinoma and multiple lymph nodes metastasis thorough computed tomography, positron emission tomography-computed tomography, endoscopy and pathology. Surgery was not suitable for this patient. Instead, he was treated with etoposide and cisplatin chemotherapy regiment, every 3 wk for 4 cycles, which caused the tumor and lymph nodes to shrink. The patient could not tolerate subsequent chemotherapy due to hematological toxicity; therefore, we performed immunotherapy (durvalumab, 1500 mg) every 4 wk. At present, the patient has received 12 cycles immunotherapy over about 1 year and continues treatment and follow-up.